New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery
Lead Research Organisation:
University of Liverpool
Department Name: Institute of Translational Medicine
Abstract
The poor absorption of many orally-dosed medicines results in the use of higher doses per administration than would be ideally delivered to maintain lower production costs, storage issues, and manufacturing capacity. For HIV and other chronic diseases, patients require a life-long commitment to therapy meaning that costs accumulate over time. This has considerable impact in low- and middle-Income countries where many chronic infectious diseases require lifelong dosing to minimise further spread and maximise the quality and length of life for infected patients, which has a knock-on effect for productivity and wider economic considerations. HIV is a specific example where doses greater than 900mg per-patient-per-day are common, leading to a considerable cost burden for healthcare providers (often local governments as well as the international community) and the prevention of wide spread access to therapy due to cost constraints. In many cases, these high doses are only required because a limited amount of the drug that is swallowed actually enters the bloodstream to provide the explicit pharmacological benefits. In some cases, the drug that stays in and passes through the gut may cause the patient considerable side-effects such as gastrointestinal disturbances. Within this grant we aim to progress a new approach to therapy formulation through to demonstration of actual benefits in healthy volunteers and establish the potential to reduce administered doses whilst maintaining the amount of drug available within the bloodstream to exert its therapeutic effect after oral dosing.
This will require the full demonstration of the potential to take our new materials technology through to pharmaceutical and regulatory approved manufacturing processes and use the material to generate a new therapy candidate. After approval for human pharmacokinetic evaluation, a small study will establish the data required to de-risk pharmaceutical and material industry investment to develop new medicines. The proposed research, therefore, considerably accelerates the outcomes of previous research towards actual impact that could provide healthcare benefits around the world. While the programme is specifically targeted at a new HIV medicine, we expect the validated platform technology to be widely applicable across indications, saving costs of treatment, enabling delivery of drugs that could otherwise not be delivered orally, and generating wealth for the UK economy through commercialisation in high income contexts.
This will require the full demonstration of the potential to take our new materials technology through to pharmaceutical and regulatory approved manufacturing processes and use the material to generate a new therapy candidate. After approval for human pharmacokinetic evaluation, a small study will establish the data required to de-risk pharmaceutical and material industry investment to develop new medicines. The proposed research, therefore, considerably accelerates the outcomes of previous research towards actual impact that could provide healthcare benefits around the world. While the programme is specifically targeted at a new HIV medicine, we expect the validated platform technology to be widely applicable across indications, saving costs of treatment, enabling delivery of drugs that could otherwise not be delivered orally, and generating wealth for the UK economy through commercialisation in high income contexts.
Planned Impact
The introduction of new pharmaceutical excipients and the clear demonstration of their value and benefits may impact widely upon academia and industry, thereby having demonstrable scientific, economic and societal benefit. Academically, new approaches to drug delivery with clear evidence of benefits in human studies are well known to spur considerable new activity and investment. The combination of concepts used within the translational pathway outlined in this research is potentially highly synergistic, encouraging researchers to engage in translation and deliver new impact through material developments that may be progressed through relevant manufacturing processes. As such, the strategy for taking model systems with academic proof-of-concept through to actual healthy volunteer demonstration will inspire other researchers to progress their healthcare innovations and create evidence that will de-risk their engagement with pharmaceutical companies and development partners alike.
Achieving matching PK from reduced concentrations of drugs in orally administered therapies has the potential to revolutionise healthcare system costs for a range of diseases, but specifically the growing cost for treatment of chronic indications. The value for HIV alone is huge (see letters of support), but a validation of the core technology opens opportunities for much more widespread uptake, and will enable us to generate additional impact from engagement with our existing (and new) commercial partners. In addition, the dossier of information generated for the new copolymer excipient will make this material a viable and scale-able option for wider provision to the drug formulation community - pharmaceutical excipients are predicted to reach an estimated $8.1bn dollar global market in coming years, thereby providing an exciting opportunity for a material company to exploit. The interest in this market is clear from the engagement of Itaconix in this programme, and if successful this offers an opportunity for a UK company to learn more within this expanding market.
It is expected that the research presented here may impact on a wide range of communities and, eventually, offer financial, economic and societal benefits. Through careful selection of the candidate therapy, the pharmacological target and the oral administration route, the team have shortened the pathway to clinical impact to potentially as little as 2 years post completion of this research - a clear acceleration of healthcare impact from initial fundamental research, which is only possible because of the foundations set by our previously EPSRC-funded research.
The laboratory researchers involved in this study will witness the translation of novel concepts through to industrial evaluation and scale-up and evidence formation through healthy volunteer studies. It is our strong hope that the impact of experiencing translation of their research will help further cement the need for truly interdisciplinary and ambitious research in the next generation of UK scientists.
Achieving matching PK from reduced concentrations of drugs in orally administered therapies has the potential to revolutionise healthcare system costs for a range of diseases, but specifically the growing cost for treatment of chronic indications. The value for HIV alone is huge (see letters of support), but a validation of the core technology opens opportunities for much more widespread uptake, and will enable us to generate additional impact from engagement with our existing (and new) commercial partners. In addition, the dossier of information generated for the new copolymer excipient will make this material a viable and scale-able option for wider provision to the drug formulation community - pharmaceutical excipients are predicted to reach an estimated $8.1bn dollar global market in coming years, thereby providing an exciting opportunity for a material company to exploit. The interest in this market is clear from the engagement of Itaconix in this programme, and if successful this offers an opportunity for a UK company to learn more within this expanding market.
It is expected that the research presented here may impact on a wide range of communities and, eventually, offer financial, economic and societal benefits. Through careful selection of the candidate therapy, the pharmacological target and the oral administration route, the team have shortened the pathway to clinical impact to potentially as little as 2 years post completion of this research - a clear acceleration of healthcare impact from initial fundamental research, which is only possible because of the foundations set by our previously EPSRC-funded research.
The laboratory researchers involved in this study will witness the translation of novel concepts through to industrial evaluation and scale-up and evidence formation through healthy volunteer studies. It is our strong hope that the impact of experiencing translation of their research will help further cement the need for truly interdisciplinary and ambitious research in the next generation of UK scientists.
Organisations
- University of Liverpool (Lead Research Organisation)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Liverpool School of Tropical Medicine (Collaboration)
- Ezintsha (Collaboration)
- Medicines Patent Pool (Collaboration, Project Partner)
- Drugs for Neglected Diseases initiative (DNDi) (Collaboration)
- Obafemi Awolowo University (Collaboration)
- Itaconix (United Kingdom) (Project Partner)
- Clinton Health Access Initiative (Project Partner)
Publications
Akinloye A
(2024)
Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers
in Future Pharmacology
Arshad U
(2020)
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
in Clinical pharmacology and therapeutics
Assmus F
(2022)
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19.
in Microorganisms
Boffito M
(2021)
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
in Clinical pharmacology and therapeutics
Box H
(2024)
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters
in Journal of Antimicrobial Chemotherapy
Box H
(2022)
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.
in bioRxiv : the preprint server for biology
Brain D
(2021)
Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.
in Advanced drug delivery reviews
Brevini T
(2023)
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
in Nature
Edwards SE
(2020)
Mucus-responsive functionalized emulsions: design, synthesis and study of novel branched polymers as functional emulsifiers.
in RSC advances
Flexner C
(2022)
The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases.
in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Fowotade A
(2022)
A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19.
in Frontiers in medicine
Gallardo-Toledo E
(2023)
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters
in Viruses
Hentzien M
(2022)
Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants
in Frontiers in Microbiology
Hiscox J
(2021)
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?
in Journal of Antimicrobial Chemotherapy
Huo J
(2021)
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.
in Nature communications
Jeffreys LN
(2022)
Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.
in International journal of antimicrobial agents
Khoo SH
(2021)
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
in The Journal of antimicrobial chemotherapy
Description | A CMO has been contracted and initial bench scale polymer synthesis has successfully been translated to the CMO under GMP conditions. Polymer synthesis was being scaled for GMP formulation to precede confirmatory pharmacokinetic studies in animals and GLP toxicology but was negatively impacted by the pandemic. For the main project formulations were selected for in vivo studies and pharmacokinetics characterised after oral, intravenous and intramuscular administration to rats. Results of these studies indicated that profound benefits in posology were not likely to arise from the selected drugs. Ongoing discussions are underway to explore different drugs and formulations for evaluation that may include options currently under consideration for COVID-19. As part of the emergency response to the COVID-19 pandemic, a portion of funding was repositioned with approval from UKRI to explore evaluation of candidates therapeutics for COVID-19. This work has been highly productive and has led to several candidates that are now progressing into various stages of development with additional funding from other agencies. In March 2021, it was agreed with EPSRC that since medicines initially targeted by the project had failed in development, they would be replaced with those for which huge progress had been made during the pandemic. It was agreed that this didnt constitute a major change in the ambition of the programme. Since then, huge progress has been made in preclinical evaluation and GMP scale-up of formulations arising from the work for clinical evaluation of these formulations in Edinburgh. |
Exploitation Route | Several of the candidates identified with the repositioned COVID-19 funding are now in clinical trials nationally and internationally as a direct outcome of the funding but with specific budgets covered from other agencies. In addition, a new formulation was identified for a putative COVID-19 application on which patents have been filed, a publication was recently accepted, and is now being translated to GMP manufacture again with funding from another agency. The work conducted in 2020 has directly resulted in several clinical trials for COVID-19 (funded by other agencies) and outcomes from these trials have been disseminated. The goal is to identify formulations of drugs with efficacy in COVID-19 and translate these to medicines that can be deployed clinically. Arising new medicines may also have broader applicability in the event of another coronavirus outbreak. |
Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |
Description | Data arising from the utilisation of the reposition funding for COVID-19 have directly resulted in selection of candidate therapeutics for several ongoing clinical trials in UK (AGILE), South Africa and Nigeria. In 2021, the phase I trial in the UK and the phase II trial in Nigeria were completed and results disseminated. The phase I/IIa trial in South Africa was completed and disseminated in 2022. Preclinical model systems developed through the project have continued to yield impact also. Data generated for candidates were reported directly into the UK-CTAP and reviewed as part of decision making for evaluation in the National COVID-19 clinical trials platforms. In addition, candidate formulations for putative SARS-CoV-2 antivirals have been identified and are being translated for GMP manufacture as part of the new objectives agreed with EPSRC in March 2021. Results of clinical evaluation of these novel formulations in Edinburgh will be disseminated once analysis is complete. There are also ongoing discussions with potential commerical and charitable partners to establish a viable route to market if the approach proves to be successful. |
Sector | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
Impact Types | Economic Policy & public services |
Description | Circadian Rhythms in the light of COVID-19: Formulating optimal time-of-day regimens for antiviral drugs using human 3D models and in silico modelling |
Amount | £343,559 (GBP) |
Funding ID | BB/W010801/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2021 |
End | 05/2023 |
Description | Design and implementation of a translational drug development platform for COVID-19 to generate preclinical evidence in support of treatment arms of the ANTICOV clinical trial |
Amount | £1,464,291 (GBP) |
Funding ID | 222489/Z/21/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2020 |
End | 12/2023 |
Description | Preclinical research of Sars-CoV2 bicyclic peptides |
Amount | £246,620 (GBP) |
Funding ID | PO001359 |
Organisation | Bicycle Therapeutics |
Sector | Private |
Country | United Kingdom |
Start | 08/2021 |
End | 12/2022 |
Description | Preclinical research of Sars-CoV2 bicyclic peptides |
Amount | £157,136 (GBP) |
Funding ID | PO001359 |
Organisation | Bicycle Therapeutics |
Sector | Private |
Country | United Kingdom |
Start | 03/2021 |
End | 08/2021 |
Description | DNDi |
Organisation | Drugs for Neglected Diseases initiative (DNDi) |
Country | Switzerland |
Sector | Charity/Non Profit |
PI Contribution | Our team have identified drugs that are potentially repurposable as antiviral interventions for SARS-CoV-2. Weekly meetings with DNDi have resulted in rapid sharing of data with them and planning experiments to plug knowledg gaps and identify a route to phase III evaluation. |
Collaborator Contribution | The team at DNDi have organised complimentary preclinical evaluations to refine Liverpool candidates for evaluation in their phase III ANTICOV platform trial. A candidate identified by Liverpool as part of the repositioned funding from this award has now been selected for evaluation in ANTICOV. |
Impact | Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. Boffito M, Back DJ, Flexner C, Sjö P, Blaschke TF, Horby PW, Cattaneo D, Acosta EP, Anderson P, Owen A. Clin Pharmacol Ther. 2020 Oct 28. doi: 10.1002/cpt.2099. Online ahead of print. PMID: 33113246 |
Start Year | 2020 |
Description | Ezintsha |
Organisation | Ezintsha |
Country | South Africa |
Sector | Charity/Non Profit |
PI Contribution | Candidates identified in Liverpool have directly progressed into two phase II trials in South Africa looking at utility in treatement or prevention of COVID-19. These candidates were identified directly using the repositioned funding from this award. |
Collaborator Contribution | The team in South Africa were instrumental in development of the protocols, approvals and drug supply. |
Impact | None yet |
Start Year | 2020 |
Description | Liverpool School of Tropical Medicine |
Organisation | Liverpool School of Tropical Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | At the start of the pandemic, a cross-campus COVID-19 community was established and preclinical assessments were conducted harmoniously as part of a collaboration with the Liverpool School of Tropical Medicine. The repositioned funding from this award was instrumental in establishing this collaboration. Our team contributed pharmacokinetic modelling and in vivo preclinical evaluation of candidate medicines for COVID-19. |
Collaborator Contribution | The LSTM team contributed in vitro assessments of candidate drugs for COVID-19 |
Impact | Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? Stachulski AV, Taujanskas J, Pate SL, Rajoli RKR, Aljayyoussi G, Pennington SH, Ward SA, Hong WD, Biagini GA, Owen A, Nixon GL, Leung SC, O'Neill PM. ACS Infect Dis. 2020 Dec 22:acsinfecdis.0c00478. doi: 10.1021/acsinfecdis.0c00478. Online ahead of print. PMID: 33352056 Free PMC article. Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini GA, Owen A. Br J Clin Pharmacol. 2020 Oct 21. doi: 10.1111/bcp.14619. Online ahead of print. PMID: 33085781 Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. Rajoli RK, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini G, Owen A. medRxiv. 2020 May 6:2020.05.01.20087130. doi: 10.1101/2020.05.01.20087130. Preprint. PMID: 32511548 Free PMC article. Updated. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A. Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14. |
Start Year | 2020 |
Description | Medicines Patent Pool |
Organisation | Medicines Patent Pool |
Country | Switzerland |
Sector | Private |
PI Contribution | CELT investigators were the first academic inventors to licence patents to MPP to reduce barriers to global product availability. |
Collaborator Contribution | Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. |
Impact | - |
Start Year | 2020 |
Description | Obafemi Awolowo University |
Organisation | Obafemi Awolowo University |
Country | Nigeria |
Sector | Academic/University |
PI Contribution | Work conducted in Liverpool as part of the repositioned funding from this award directly resulted in identification of a potential combination for SARS-CoV-2, which has progressed into a phase II trial in partnership with the Nigerian collaborator. |
Collaborator Contribution | The team in Nigeria were instrumental in developing the clinical protocol and securing approvals and drug supply for the NACOVID trial. |
Impact | Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Olagunju A, Fowotade A, Olagunoye A, Ojo TO, Adefuye BO, Fagbamigbe AF, Adebiyi AO, Olagunju OI, Ladipo OT, Akinloye A, Adeagbo BA, Onayade A, Bolaji OO, Happi C, Rannard S, Owen A. Trials. 2021 Jan 4;22(1):3. doi: 10.1186/s13063-020-04987-8. |
Start Year | 2020 |
Description | The University of Edinburgh |
Organisation | University of Edinburgh |
Department | MRC Centre for Inflammation Research |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Kev Dhaliwal is Professor of Molecular Imaging & Healthcare Technology and a Consultant in Respiratory Medicine. We have established strong links with the Translational Healthcare Technologies Group for which he is director and are in mature discussions to finalise design of a phase 1a clinical trial to assess formulations that have been directly developed as part of our EPSRC funding. Our team have contributed all materials development and understanding, oversight of GMP translation and scale-up, and preclinical proof of concept of the developed formulations. |
Collaborator Contribution | The team in Edinburgh have leveraged their networks to derisk clinical translation through access to GLP toxicology data for the drug under investigation. In addition, they are contributing early stage clinical trials expertise for protocol development and will also execute the trial in Edinburgh. |
Impact | Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters. Neary M, Box H, Sharp J, Tatham L, Curley P, Herriott J, Kijak E, Arshad U, Hobson JJ, Rajoli R, Pertinez H, Valentijn A, Dhaliwal K, McCaughan F, Rannard SP, Kipar A, Stewart JP, Owen A. bioRxiv. 2021 Jul 8:2021.07.08.451654. doi: 10.1101/2021.07.08.451654. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. Quinn TM, Gaughan EE, Bruce A, Antonelli J, O'Connor R, Li F, McNamara S, Koch O, MacKintosh C, Dockrell D, Walsh T, Blyth KG, Church C, Schwarze J, Boz C, Valanciute A, Burgess M, Emanuel P, Mills B, Rinaldi G, Hardisty G, Mills R, Findlay EG, Jabbal S, Duncan A, Plant S, Marshall ADL, Young I, Russell K, Scholefield E, Nimmo AF, Nazarov IB, Churchill GC, McCullagh JSO, Ebrahimi KH, Ferrett C, Templeton K, Rannard S, Owen A, Moore A, Finlayson K, Shankar-Hari M, Norrie J, Parker RA, Akram AR, Anthony DC, Dear JW, Hirani N, Dhaliwal K. EBioMedicine. 2022 Feb;76:103856. doi: 10.1016/j.ebiom.2022.103856. Epub 2022 Feb 11. |
Start Year | 2022 |
Description | CELT blog post: Data analysis, Modelling and accelerating development of Long-acting therapeutics |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Blog post to raise awareness of research undertaken by CELT scientists and disseminate potential impact of long-acting therapeutics. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/blog/developing-the-lo... |
Description | Due diligence |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Thursday 13th December 2018 - Due diligence meeting with ChemCon GmbH, Engesserstraße 4B, 79108 Freiburg im Breisgau, Germany |
Year(s) Of Engagement Activity | 2018 |
Description | Due diligence |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Friday 15th February 2019 - Due diligence meeting with ChemConnection B.V., Kloosterstraat 9, 5349 AB Oss, Netherlands |
Year(s) Of Engagement Activity | 2019 |
Description | Due diligence |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Friday 24th August 2018 - Due diligence meeting with PCI Synthesis 9 Opportunity Way, Newburyport, MA 01950, USA |
Year(s) Of Engagement Activity | 2018 |
Description | Interview for WIRED magazine: The search is on for a drug that can stop Covid-19 infections |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Interview for WIRED magazine: The search is on for a drug that can stop Covid-19 infections |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.wired.co.uk/article/preventative-treatments-covid-19 |
Description | News article: Researchers from the Centre of Excellence for Long-acting Therapeutics featured prominently in leading scientific journal for clinical infectious diseases |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | News article raising awareness of CELT researchers impact in leading scientific journal for clinical infectious diseases. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/news/stories/title,136... |
Description | Press Release: University plays a key role in Investment Zone Plans |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Initial launch of Liverpool City Region Combined Authority's Investment Zone plans including Hemisphere One building and what that means for the Centre of Excellence in Long-acting Therapeutics. |
Year(s) Of Engagement Activity | 2024 |
URL | https://news.liverpool.ac.uk/2024/03/12/university-plays-key-role-in-investment-zone-plans/ |
Description | Press release: AGILE COVID-19 drug testing platform opens new trial in South Africa |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Press release announcing AGILE clinical trials platform opening a new testing site in South Africa to test drugs to treat COVID19 |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/news/articles/agile-co... |
Description | Press release: Liverpool launches new Centre of Excellence for Long-acting Therapeutics |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Press release announcing The University of Liverpool launching a new research centre for the development of revolutionary long-acting medicines established as part of a £30.5 million ($40m) international research consortium, primarily funded by Unitaid. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/news/articles/liverpoo... |
Description | Press release: Long-acting injectable medicine as potential route to COVID-19 therapy |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Press release announcing researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/news/articles/long-act... |
Description | Press release: Off-patent liver disease drug could prevent COVID-19 infection |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Press release relating to 'FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2' published in 'Nature' journal 5/12/2022 |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/news/articles/off-pate... |
Description | Press release: Two new therapies to be tested in ground-breaking COVID-19 clinical trial |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Press release announcing two new therapies are to be studied in patients as part of the ground-breaking AGILE clinical trial platform, with the hope of finding treatments for people with COVID-19. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/news/articles/two-new-... |
Description | Professor Steve Rannard Awarded Macro Group UK Award |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Professor Steve Rannard, Co-Director of CELT has been awarded the Macro Group UK Medal in recognition of his significant and substantial contribution to the development of polymer science, and for his services to the UK polymer science community. |
Year(s) Of Engagement Activity | 2024 |
URL | https://news.liverpool.ac.uk/2024/01/22/professor-steve-rannard-awarded-macro-group-uk-medal/ |
Description | Researchers Continue to Provide Global Understanding of COVID-19 |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | A press release to highlight the work from CELT and other University teams to translate COVID-19 antiviral treatments |
Year(s) Of Engagement Activity | 2023 |
URL | https://news.liverpool.ac.uk/2023/06/26/researchers-continue-to-support-global-understanding-of-covi... |